<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34622706</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1545-1550</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists</Title>
          <ISOAbbreviation>J Endovasc Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience.</ArticleTitle>
        <Pagination>
          <StartPage>350</StartPage>
          <EndPage>360</EndPage>
          <MedlinePgn>350-360</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/15266028211049339</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Few industry sponsored trials reported satisfactory outcomes in the use of drug-eluting stents (DES) for treatment of femoropopliteal arterial disease. This study analyzed the early/late clinical outcome from a real world single center.</AbstractText>
          <AbstractText Label="PATIENT POPULATIONS/METHODS">A total of 115 limbs treated with Zilver PTX were analyzed for: major adverse limb event (MALE: above ankle limb amputation/major intervention at 1 year), major adverse events (MAEs; death, amputation, and target lesion thrombosis/reintervention), primary patency (based on duplex ultrasound ± ankle brachial indexes), limb salvage, and amputation free survival rates (AFS) at 1 and 2 years.</AbstractText>
          <AbstractText Label="RESULTS">Indications included claudication in 32% and critical limb threatening ischemia (CLTI) in 68%. Lesions treated included: superficial femoral artery (SFA) 66%, both SFA and popliteal artery (PA) 19% and PA 15%. Mean lesion length was 21 cm and 68% had total occlusion. 45% were Trans-Atlantic Inter-Society Consensus (TASC) TASC II D lesions and 55% A-C lesions. Mean follow-up was 18.4 months (1-76 months). Perioperative major morbidity rate was 8.7% with 0% mortality. MALE rate at 1 year was 17% (13.5% for claudication vs 19.2% for CLTI, p=0.4499). MAE rate was 30% for claudication versus 52% for CLTI (p=0.0392). Overall primary patency rates at 1 and 2 years were 75% and 54% (86% and 71% for claudication vs 70% and 46% for CLTI, respectively, p=0.0213). Primary patency rates at 1 and 2 years were 94% and 88% for TASC A-C lesions versus 50% and 16% for TASC D lesions (p&lt;0.0001). Overall freedom from MALE rate at 1 and 2 years were 85% and 79% (86% and 86% for claudication vs 84% and 74% for CLTI, p=0.2391). These rates were 96% and 93% for TASC A-C lesions versus 70% and 50% for D lesions, respectively (p&lt;0.0001). Limb salvage rates at 1 and 2 years were 93% and 86% (100% and 100% for claudication vs 89% and 78% for CLTI, p=0.012). Overall AFS rates at 1 and 2 years were 79% and 71% (93% and 82% for TASC A-C vs 59% and 59% for D lesions, p=0.001).</AbstractText>
          <AbstractText Label="CONCLUSION">Clinical outcomes after DES (Zilver PTX) in femoropopliteal arterial lesions were satisfactory for TASC A-C lesions but inferior/unsatisfactory for TASC D lesions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>AbuRahma</LastName>
            <ForeName>Ali F</ForeName>
            <Initials>AF</Initials>
            <Identifier Source="ORCID">0000-0001-9524-5577</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, West Virginia University-Charleston Division, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beasley</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, West Virginia University-Charleston Division, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>AbuRahma</LastName>
            <ForeName>Zachary T</ForeName>
            <Initials>ZT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, West Virginia University-Charleston Division, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davis</LastName>
            <ForeName>Meghan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, West Virginia University-Charleston Division, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adams</LastName>
            <ForeName>Elliot</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, West Virginia University-Charleston Division, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dean</LastName>
            <ForeName>L Scott</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>CAMC Institute for Academic Medicine, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shapiro</LastName>
            <ForeName>Jake</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>TriHealth Vascular Surgery, Cincinnati, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scott</LastName>
            <ForeName>Grant</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cox Health, Springfield, MO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davis</LastName>
            <ForeName>Elaine</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>CAMC Institute for Academic Medicine, Charleston, WV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Endovasc Ther</MedlineTA>
        <NlmUniqueID>100896915</NlmUniqueID>
        <ISSNLinking>1526-6028</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001157" MajorTopicYN="Y">Arterial Occlusive Diseases</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005263" MajorTopicYN="N">Femoral Artery</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007383" MajorTopicYN="N">Intermittent Claudication</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023821" MajorTopicYN="N">Limb Salvage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058729" MajorTopicYN="Y">Peripheral Arterial Disease</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011150" MajorTopicYN="N">Popliteal Artery</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014654" MajorTopicYN="N">Vascular Patency</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">critical limb ischemia</Keyword>
        <Keyword MajorTopicYN="Y">drug-eluting stent</Keyword>
        <Keyword MajorTopicYN="Y">femoropopliteal occlusive disease</Keyword>
        <Keyword MajorTopicYN="Y">neointimal hyperplasia</Keyword>
        <Keyword MajorTopicYN="Y">percutaneous transluminal angioplasty</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>8</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34622706</ArticleId>
        <ArticleId IdType="doi">10.1177/15266028211049339</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
